STOCK TITAN

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Qilian International Holding Group Limited (NASDAQ: QLI) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company intends to regain compliance by July 8, 2024, and is considering a reverse stock split if necessary. The ordinary shares will continue to be listed and traded on the Nasdaq Capital Market.
Positive
  • None.
Negative
  • The company is at risk of potential delisting if it fails to meet the minimum bid price requirement by the extended deadline.

Insights

The extension provided by Nasdaq for Qilian International Holding Group Limited to meet the minimum bid price requirement is a pivotal moment for the company. The ability to maintain a listing on a major exchange like Nasdaq is crucial for investor confidence and the accessibility of the stock to institutional investors. The stipulation that the stock must trade at or above $1.00 for a minimum of 10 consecutive business days is a standard regulatory measure to ensure a degree of stability and market trust in the listed entities.

From a financial perspective, the consideration of a reverse stock split indicates the company's proactive approach to addressing the compliance issue. While this can be a red flag signaling underlying financial issues, it is also a common strategic move to elevate stock prices by reducing the number of shares outstanding, thereby potentially making the stock more attractive to certain investors. The impact on the company's market capitalization is neutral in theory, but the market reaction can vary. Investors will be watching closely for the company's ability to improve its fundamentals and market perception, which are the ultimate drivers of stock value.

Qilian's situation serves as a case study on the importance of stock market compliance for publicly traded companies. The extension period is not only a grace period but also a critical timeframe for the company to execute strategic initiatives that may influence investor sentiment. The market's response to such compliance-related news can be mixed; while some investors may see this as a sign of potential turnaround, others may perceive it as a symptom of deeper financial troubles.

Historically, companies facing delisting risks often experience increased volatility in their stock price as the market digests the implications. The announcement itself can act as a catalyst for trading activity. For Qilian, maintaining operations without disruption is essential to reassure stakeholders. However, the long-term success of the company in the market will depend on its operational performance and the effectiveness of its strategies to boost share price organically, such as improving earnings, expanding its market share, or innovating within its product lines.

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

The Company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before July 8, 2024 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company's business.

About Qilian International Holding Group Ltd

Qilian International Holding Group Ltd, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at http://ir.qlsyy.net

Safe Harbor Statement

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

For more information, please contact:

Name: Yubin Jiang

Email: QLI@qlsyy.net 

Cision View original content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-receives-180-day-extension-from-nasdaq-to-meet-minimum-bid-price-rule-302033515.html

SOURCE Qilian International Holding Group Limited

FAQ

What is the latest announcement from Qilian International Holding Group Limited (NASDAQ: QLI)?

The company received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement.

What is the deadline for Qilian International Holding Group Limited (NASDAQ: QLI) to regain compliance with Nasdaq's minimum bid price requirement?

The company has until July 8, 2024, to regain compliance.

What options is Qilian International Holding Group Limited (NASDAQ: QLI) considering to regain compliance with the minimum bid price requirement?

The company is considering all available options, including a reverse stock split if necessary.

What will happen if Qilian International Holding Group Limited (NASDAQ: QLI) fails to meet the minimum bid price requirement by the extended deadline?

The company is at risk of potential delisting if it fails to meet the minimum bid price requirement by the extended deadline.

Qilian International Holding Group Ltd. Ordinary Shares

NASDAQ:QLI

QLI Rankings

QLI Latest News

QLI Stock Data

38.68M
7.15M
77.45%
0.04%
0.4%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Jiuquan